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The results of cost-effectiveness illustrate that quetiapine is dominant in 
Russian patients with bipolar disorder who are initiating atypical antipsychotics 
therapy compared with aripiprazole, olanzapine or ziprasidone.  
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OBJECTIVES: To explore the cost-effectiveness of quetiapine, aripiprazole or 
olanzapine in Russian Federation (RF) patients with bipolar disorder (BPD) 
depression episodes. METHODS: A cost-effectiveness analysis (CEA) was 
developed to estimate the cost-effectiveness of quetiapine compared with 
aripiprazole or olanzapine. CEA was undertaken from RF health care perspective 
using discount rate of 5%. The time horizon of the analysis was ne year for using 
preventive relapse rates and five years for QALY. Direct health care expenses 
associated with bipolar disorder and resulting follow-up costs were calculated 
using general tariff agreement of Russian obligatory insurance system and 
official national statistics. For reference, accepted exchange rate was 1 EUR = 40 
RUB. RESULTS: Taking into account rates of prevented relapse following cost-
effectiveness ratios (CER) were obtained: 156,915 RUB (3,923 EUR) in quetiapine 
group, 429,362 RUB (10,734 EUR) in aripiprazole group and 221,879 RUB (5,547 
EUR) in olanzapine group. Using QALY values CER were accounted for: 185,236 
RUB (4,631 EUR) in quetiapine group, 478,433 RUB (11,961 EUR) in aripiprazole 
group and 254,100 RUB (6,353 EUR) in olanzapine group. CONCLUSIONS: 
Quetiapine in the treatment of BPD depression episodes is a dominant compared 
with aripiprazole or olanzapine.  
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OBJECTIVES: To assess the efficiency of the atypical antipsychotics used to 
reduce relapses in bipolar disorder, taking into account costs and effectiveness 
(measured as QALY). METHODS: The Russian health care system perspective and 
a 5 year temporal horizon have been used. An annual discount rate assumed was 
of 5%. Taking into account the last literature review on bipolar disorder, four 
fundamental aspects related with bipolar disorder management were analyzed: 
relapse rates, inpatient treatment, outpatient treatment and hospitalization 
rates. The health care direct costs corresponding to the drug acquisition costs 
have been analyzed together with the costs of inpatient diagnostics, costs of 
inpatient treatment and costs of hospitality relapses (stay and drug cost) 
updated with data from Russian health care system. RESULTS: Quetiapine or 
risperidone treatment presents the lower total costs (€13,562 and €13,097 
respectively) compared with the other strategies (aripiprazole = €36,328 and 
olanzapine = €19,957). Quetiapine presents the higher efficacy (QALY) compared 
with the alternatives (quetiapine = 3.551, risperidone = 3.534, aripiprazole = 3.528 
and olanzapine = 3.525). With these results one can emphasize that quetiapine 
or risperidone treatment is dominant with the cost-effectiveness ratio (CER) of 
3819 and 3706, respectively, versus aripiprazole or olanzapine groups (CER 10,297 
and 5,662 respectively). The incremental CER (quetiapine vs. risperidone) is 
€27,322 per QALY. CONCLUSIONS: The results of cost-effectiveness illustrate 
that quetiapine is dominant compared with aripiprazole or olanzapine. Also 
quetiapine therapy is within willingness to pay threshold in case of risperidone 
substitution in Russian patients with bipolar disorder who are initiating atypical 
antipsychotics therapy.  
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OBJECTIVES: Attention Deficit/Hyperactivity Disorder (ADHD) is a 
neurobehavioral disorder and one of the most prevalent chronic health problems 
affecting school-age children, representing a costly major public health problem. 
Keeping in view, the substantial economic burden, the objective of this study 
was to conduct a cost-minimization analysis of once-a-day extended-release (ER) 
versus two-times-daily immediate-release (IR) methylphenidate for the 
treatment of ADHD patients. METHODS: Major literature databases were 
systematically searched to identify appropriate randomized clinical trials and 
meta-analyses to obtain costs associated with both the alternative formulations 
from a payers (third party) perspective. Medical costs included cost of drug, cost 
of assessments, cost of non-compliance, cost of injuries/accidents and cost of in-
school administration and were obtained from published literature. All costs 
were adjusted to 2012 USD using consumer price index. The expected outcome 
was considered to be the same for both the formulations and a cost 
minimization analysis was performed using a decision tree approach. Multiple 
one-way sensitivity analyses were performed on all cost variables to evaluate the 
robustness of the results. RESULTS: The ER regimen of methylphenidate resulted 
in a total annual cost of $4685 per patient which was less costly as compared to 
the IR regimen that resulted in a total annual cost of $9524 per patient for the 
treatment of ADHD. One-way sensitivity analyses results were consistent. 
CONCLUSIONS: In our study Methylphenidate ER had 50.81% less annual 
economic burden as compared to the IR regimen for the treatment of ADHD 
patients.  
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OBJECTIVES: Different types of psychotherapy, alone or together with 
pharmaceuticals, are used extensively in the treatment of depressive and 
anxiety disorders. However, only a few studies thus far have addressed the cost-
utility of different psychotherapies. The aim of this study is to compare the 
direct health care costs and the quality of life of persons who have suffered from 
depression or anxiety and have been treated either with short-term 
psychodynamic psychotherapy (SPP) or solution-focused therapy (SFT). The 
follow-up period was three years. METHODS: A total of 198 outpatients aged 20–
45 years suffering from mood or anxiety disorder were randomized to SPP or SFT. 
Patients’ quality of life was assessed using Chubon’s Life Situation Survey (LSS). 
The assessments took place at baseline and at 7, 12 and 36 months after the start 
of the therapy. All direct costs due to mental health problems incurred during 
the three-year follow-up period were taken into account in the analysis. 
RESULTS: During the first 7 months patients’ quality of life improved 
considerably, with mean LSS scores increasing from about 79 to about 93 in both 
groups. This change was also statistically significant. After the 7th month some 
minor improvements continued to be observed in quality of life. At the end of 
the follow-up period the mean LSS scores were in both groups somewhat below 
100, a threshold for very good life quality. The differences between the two 
groups were very small at every measurement point and not statistically 
significant. The direct costs were about equal in both groups. The small positive 
changes observed in the quality of life after the 7th month were at least partly 
due to auxiliary treatments whose costs were much higher than the costs of SPP 
or SFT. CONCLUSIONS: There is little appreciable difference in cost-utility 
between SPP and SFT.  
 
PMH42  
HEALTH CARE AND SOCIAL SERVICE USE AND COST IN DEPRESSED AFRICAN 
AMERICAN ELDERS: RESULTS FROM THE BEAT THE BLUES RANDOMIZED 
CLINICAL TRIAL  
Pizzi LT1, Jutkowitz E2, Frick KD3, Suh DC4, Prioli KM1, Gitlin L5 
1Thomas Jefferson University, Philadelphia, PA, USA, 2University of Minnesota, Minneapolis, MN, 
USA, 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 4Chung-Ang 
University, Seoul, South Korea, 5Johns Hopkins University, Baltimore, MD, USA  
OBJECTIVES: To report health care and social service costs from a trial of 
nonpharmacologic depression support program in older African Americans, Beat 
the Blues (BTB). METHODS: Two-group randomized design in which the BTB 
group received the program and the control group did not receive the program. 
BTB employed licensed senior center social workers to meet with participants 
(up to 10 sessions). Components of BTB were depression education, care 
management, stress reduction, referrals and linkages, and behavioral activation. 
Both groups were followed for 4 months. Service use and costs at each time point 
included health care use for depression (outpatient calls and visits to physician, 
emergency department visits, hospitalizations), medications, alternative 
approaches to managing depression (massage, acupuncture), paid caregiving 
(homemaker, home health aide, and visiting nurse), and social services (meals, 
transportation, and social worker support). RESULTS: A total of 129 subjects were 
randomized (68 BTB, 61 wait-list control); the average age was 68.3 years, most 
were female (77.9%), not married (90.4%), not employed (92%), and had an 
average of 6.4 health conditions (range 1-19). In both groups, costs for health care 
use for depression and alternative approaches to managing depression were 
similar at baseline. Medication costs for BTB decreased from $210 at baseline to 
$159 at 4 months, whereas in the wait-list control group, medication costs 
remained roughly constant ($186 at baseline and $197 at 4 months). Both groups 
experienced a decrease in paid caregiving costs ($69 in the BTB group vs. $39 in 
the wait-list control group). The BTB group experienced an overall cost decrease 
of $112 versus $19 in the wait-list control group over the 4 months. 
CONCLUSIONS: Decreases in medication and caregiving costs resulted in a net 
lower cost in the BTB group during observation period. Larger scale translational 
studies are needed to understand the extent to which BTB influences specific 
types of costs.  
 
MENTAL HEALTH – Patient-Reported Outcomes & Patient Preference Studies 
 
PMH43  
USE OF A DECISION TREE MODEL TO ESTIMATE THE ECONOMIC BENEFITS OF 
REDUCING SCHIZOPHRENIA ILLNESS RELAPSE  
Furiak N1, Klein RW1, Gahn JC1, Camper SB2, Summers K3 
1Medical Decision Modeling Inc., Indianapolis, IN, USA, 2Endo Pharmaceuticals Inc., Chadds Ford, 
PA, USA, 3Endo Pharmaceuticals, Inc., Chadds Ford, PA, USA  
OBJECTIVES: To quantify the direct medical resources used and the 
corresponding burden of disease in the treatment of patients with 
schizophrenia. Because low-frequency administration (LFA) of risperidone 
guarantees adherence during treatment intervals and offers fewer opportunities 
to discontinue, adherence and persistence were assumed to improve, thereby 
reducing relapses of major symptoms. METHODS: A decision tree model 
including Markov processes with monthly cycles and a five-year maximum 
timeframe was constructed. Costs were adapted from the literature and 
discounted at a 3% annual rate. The population is a demographically 
homogeneous cohort of patients with schizophrenia, differentiated by initial 
